Patents Examined by Jeanine Goldberg
  • Method and kit for detecting bacterium of genus
    Patent number: 11203789
    Abstract: A method for detecting a bacterium of the genus Novosphingobium, includes a first step of amplifying nucleotides using a test DNA as a template and primers capable of amplifying a nucleotide sequence of consecutive 94 or more nucleotides and 136 or less nucleotides in the nucleotide sequence of SEQ ID NO: 1 to obtain an amplified product; and a second step of detecting the amplified product.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: December 21, 2021
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventor: Tomokazu Mitsui
  • Method and kit for determining the tissue or cell origin of DNA
    Patent number: 11203784
    Abstract: A method of detecting death of a cell type or tissue in a subject is disclosed. The method comprises determining whether cell-free DNA comprised in a fluid sample of the subject is derived from the cell type or tissue, wherein the determining is effected by ascertaining the methylation status of at least four methylation sites on a continuous sequence of the cell-free DNA, the sequence comprising no more than 300 nucleotides, wherein a methylation status of each of the at least four methylation sites on the continuous sequence of the DNA characteristic of the cell type or tissue is indicative of death of the cell type or tissue. Kits for detecting cell death are also disclosed.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: December 21, 2021
    Assignees: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Yuval Dor, Ruth Shemer, Benjamin Glaser
  • Method for predicting and monitoring response to an immune checkpoint inhibitor
    Patent number: 11186878
    Abstract: A method for analyzing cell free DNA (cfDNA) from the bloodstream of a cancer patient is provided. In some embodiments, the method may comprise sequencing at least part of the coding sequences of TP53 and KRAS in a sample of the cfDNA, analyzing the sequences to identify nucleotide transversions in the coding sequences of the genes, relative to reference sequences of the genes. In some embodiments, the method may comprise counting the total number of identified nucleotide transversions. The presence of nucleotide transversions indicates that the patient will be more responsive to the immune checkpoint inhibitor, whereas a decreased number of transversions or no transversios indicates that the patient will be less responsive to the immune checkpoint inhibitor.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: November 30, 2021
    Assignee: INIVATA LTD.
    Inventors: John Beeler, Vincent Plagnol, Greg Jones
  • Methods for reducing drug-induced liver injury
    Patent number: 11180547
    Abstract: The present disclosure provides methods of treating a patient with infliximab or alternative therapies to reduce the risk of developing, and/or severity of, an adverse drug reaction such as drug-induced liver injury. The methods include identifying patients at risk for developing DILI by determining the presence or absence of one or more HLA alleles in the patients.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: November 23, 2021
    Assignee: TEN PEAKS LLC
    Inventors: Sundar Srinivasan, Christina Chow
  • Methods, kits, and devices utilizing HTR2C polymorphisms for diagnosing, prognosing, and treating psychiatric disorders in a patient
    Patent number: 11174514
    Abstract: Disclosed are methods, kits, and devices for diagnosing and treating psychiatric, disorders and the symptoms thereof. The methods, kits, and devices relate to identifying genetic markers that may be utilized to diagnose and/or prognose a patient and treat the diagnosed and/or prognosed patient by administering a drug the patient based on the genetic marker having been identified. Genetic markers identified in the methods may include HTR2C polymorphisms such as a polymorphism resulting in a Cys23Ser amino acid substitution, an rs3813929 (?759C/T) polymorphism, and an rs518147 (?697G/C) polymorphism).
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: November 16, 2021
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Jiang Li, Herbert Y. Meltzer
  • Methods and compositions for screening and treating developmental disorders
    Patent number: 11174516
    Abstract: This document provides methods and materials related to genetic variations of developmental disorders. For example, this document provides methods for using such genetic variations to assess susceptibility of developing Autism Spectrum Disorder.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: November 16, 2021
    Assignees: The Hospital for Sick Children, Population Bio, Inc.
    Inventors: Eli Hatchwell, Peggy S. Eis, Stephen Scherer, Aparna Prasad
  • Methods for depleting RNA from nucleic acid samples
    Patent number: 11149297
    Abstract: The invention relates to methods of depleting RNA from a nucleic acid sample. The RNA may be any RNA, including, but not limited to, rRNA, tRNA, and mRNA. The method is useful for depleting RNA from a nucleic acid sample obtained from a fixed paraffin-embedded tissue (FPET) sample. The method may also be used to prepare cDNA, in particular, a cDNA library for further analysis or manipulation.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: October 19, 2021
    Assignee: Genomic Health, Inc.
    Inventors: Dominick Sinicropi, John Morlan
  • Genetic abnormalities in plasma cell dyscrasias
    Patent number: 11124838
    Abstract: Provided herein are non-invasive methods and biomarkers that identify progression and clonal evolution of plasma cell dyscrasias. Also provided are materials and methods for the diagnosis, prognosis, staging, and monitoring of plasma cell dyscrasias based on the presence of the bio markers in a blood biopsy, as well as methods for monitoring the progression of a plasma cell dyscrasia, determining the efficacy of a therapeutic agent, determining a targeted therapy related to a plasma cell dyscrasia, and/or treating a plasma cell dyscrasia. The methods provided herein provide several advantages over invasive biopsies.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: September 21, 2021
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Irene Ghobrial, Salomon Manier, Yuji Mishima
  • Method and kit for detecting bacteria of genus nitrobacter
    Patent number: 11124843
    Abstract: Provided is a method for detecting a bacterium of the genus Nitrobacter, comprising: a first step of amplifying a nucleotide using a test DNA as a template and primers capable of amplifying a nucleotide sequence of consecutive 110 nucleotides or more and 157 nucleotides or less in the nucleotide sequence set forth in SEQ ID NO: 1 to obtain an amplified product; and a second step of detecting the amplified product.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: September 21, 2021
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventor: Tomokazu Mitsui
  • Methods for reducing drug-induced liver injury
    Patent number: 11124566
    Abstract: The present disclosure provides methods of treating a patient with infliximab or alternative therapies to reduce the risk of developing, and/or severity of, an adverse drug reaction such as drug-induced liver injury. The methods include identifying patients at risk for developing DILI by determining the presence or absence of one or more HLA alleles in the patients.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: September 21, 2021
    Assignee: TEN PEAKS LLC
    Inventors: Sundar Srinivasan, Christina Chow
  • Compositions and methods for performing methylation detection assays
    Patent number: 11118230
    Abstract: Provided herein is technology relating to performing methylation assays. In particular, the technology relates to internal controls for methylation assays.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: September 14, 2021
    Assignees: Exact Sciences Development Company, LLC, Mayo Foundation for Medical Education and Research
    Inventors: David Alan Ahlquist, William Russell Taylor, Douglas W. Mahoney, Graham P. Lidgard, Hatim T. Allawi, Abram Michael Vaccaro
  • Methods, kits and compositions pertaining to the suppression of the detectable probe binding to randomly distributed repeat sequences genomic nucleic acid
    Patent number: 11111525
    Abstract: This invention is directed to methods, kits, non-nucleotide probes as well as other compositions pertaining to the suppression of binding of detectable nucleic acid probes to undesired nucleotide sequences of genomic nucleic acid in assays designed to determine target genomic nucleic acid.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: September 7, 2021
    Assignees: Applied Biosystems, LLC, Agilent Technologies, Inc.
    Inventors: Kirsten Vang Nielsen, Jens Hyldig-Nielsen, Brett F. Williams
  • Detecting esophageal disorders
    Patent number: 11104960
    Abstract: Provided herein is technology for esophageal disorder screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of esophageal disorders (e.g., Barrett's esophagus, Barrett's esophageal dysplasia, etc.). In addition, the technology provides methods, compositions and related uses for distinguishing between Barrett's esophagus and Barrett's esophageal dysplasia, and between Barrett's esophageal low-grade dysplasia, Barrett's esophageal high-grade dysplasia, and esophageal adenocarcinoma within samples obtained through endoscopic brushing or nonendoscopic whole esophageal brushing or swabbing using a tethered device (e.g. such as a capsule sponge, balloon, or other device).
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: August 31, 2021
    Assignees: Exact Sciences Development Company, LLC, Mayo Foundation for Medical Education and Research
    Inventors: David A. Ahlquist, William R. Taylor, John B. Kisiel, Douglas W. Mahoney, Tracy C. Yab, Graham P. Lidgard, Hatim T. Allawi
  • Methods, tools and systems for the prediction and assessment of gestational diabetes
    Patent number: 11085082
    Abstract: Provided is a method of assessing Gestational Diabetes Mellitus (GDM) susceptibility in a female human subject, the method comprising determining the identity of at least one allele at each of at least two positions of single nucleotide polymorphism (SNP) selected from: TCF7L2—rs7903146; IGF2BP2—rs4402960; CDKN2A/B—rs10811661; SLC16A11—rs13342232; FTO—rs8050136; SLC30A8—rs13266634; CDC123/CAMK1D—rs12779790; KCNQ1—rs2237892; CUBN—rs11254363; CUBN—rs1801222; FIGN—rs2119289; FIGN—rs982393; MTHFR—rs1801131; MTHFR—rs1801133; MTR—rs1805087; and SLC19A1—rs1051266, and/or an SNP in linkage disequilibrium therewith at r2>0.8. Also provided are genotyping tools and risk assessment systems for use in the method of assessing GDM susceptibility.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: August 10, 2021
    Assignee: Patia Biopharma S.A. de C.V.
    Inventors: Laureano Simón Buela, Mirella G. Zulueta, Teresa Tusié
  • Gene mutations and copy number alterations of EGFR, KRAS and MET
    Patent number: 11085086
    Abstract: Sequence variants and copy number variations in the EGFR, KRAS and MET genes are biomarkers for resistance to anti-EGFR therapies for cancer. This disclosure provides methods of detecting these biomarkers and using them in the diagnosis and treatment of cancer.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: August 10, 2021
    Assignee: Guardant Health, Inc.
    Inventors: Scott Kopetz, AmirAli Talasaz
  • Detecting pancreatic high-grade dysplasia
    Patent number: 11078543
    Abstract: Provided herein is technology for pancreatic high-grade dysplasia screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of pancreatic high-grade dysplasia (IPMN-HGD, PanIN-3, or PDAC).
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: August 3, 2021
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: David A. Ahlquist, William R. Taylor, John B. Kisiel, Tracy C. Yab, Douglas W. Mahoney
  • DNA methylation and genotype specific biomarker for predicting post-traumatic stress disorder
    Patent number: 11072828
    Abstract: The present invention relates to the field of biomarkers. More specifically, the present invention relates to the use of biomarkers to predict post-traumatic stress disorder (PTSD). In one embodiment, a method for predicting PTSD in a subject comprises the steps of (a) measuring the DNA methylation level of a CpG dinucleotide in the 3? untranslated region of SKA2; (b) identifying the genotype at a SNP within the 3? UTR of SKA2, and (c) predicting PTSD in the subject using a prediction algorithm.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: July 27, 2021
    Assignees: The Johns Hopkins University, UMC UTRECHT HOLDING B.V.
    Inventors: Zachary Kaminsky, Marco Paul Maria Boks
  • Methods for diagnosing and treating cancer by means of the expression status and mutational status of NRF2 and downstream target genes of said gene
    Patent number: 11066709
    Abstract: The invention provides methods of identifying a subject having cancer, such as lung cancer, by analyzing expression levels of one or more NRF2 splice variants or NRF2 target genes. The invention also provides methods of treating cancer in a subject with a NRF2 pathway antagonist, wherein the subject expresses one or more NRF2 splice variants or overexpresses one or more NRF2 target genes.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: July 20, 2021
    Assignees: Genentech, Inc., Foundation Medicine, Inc.
    Inventors: Christiaan Nicolaas Klijn, James Lee, David Hugh Stokoe, Robert Gentleman, Florian Gnad, Leonard David Goldstein, Juliann Chmielecki, Ryan J. Hartmaier
  • Methods and materials for staging and treating skin cancer
    Patent number: 11060151
    Abstract: This document provides methods and materials for staging and treating skin cancer (e.g., metastatic malignant pigmented skin lesions). For example, methods and materials for using an ITLP expression profile and/or models including an ITLP expression profile to stage skin cancer and/or determine treatment options for skin cancer patients are provided.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: July 13, 2021
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Alexander Meves
  • Prediction of sleep parameter and response to sleep-inducing compound based on PER3 VNTR genotype
    Patent number: 11060144
    Abstract: The invention relates to the prediction of a sleep parameter (e.g., sleep efficiency (SE), latency to persistent sleep (LPS), wake after sleep onset (WASO), total sleep time (TST)) of an individual and the response of such an individual to a sleep inducing compound based on the individual's PER3 variable number tandem repeat (VNTR) genotype.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: July 13, 2021
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Christian Lavedan, Mihael H. Polymeropoulos, Gunther Birznieks